Reports and White Papers
Reports and white papers on political and regulatory developments with commercial consequences, risk exposure in China- and Middle East-linked supply chains, subnational opportunities across United States, and the strategic questions investors and operators are asking about.
Analysis Built for Decision-Makers
Every report reflects the caliber of analysis we deliver to clients directly, informed by decades inside Capitol Hill, the White House, national security agencies, the media, state governments, and through the relationships we maintain across the United States and around the world.
New reports are added periodically – processing the conversations, analysis, and formal research conducted by our team. Our observations reflect engagement with senior government leaders, journalists, think tank experts, academics, state and local officials, and industry executives. Check back, or reach out to talk through implications for your organization.
Critical Dose
America's Pharmaceutical ReckoningA drug-by-drug analysis of eleven widely used generic medicines — from precursor chemicals through active ingredients to finished dose — and of the federal policy framework that has not kept pace with the risk.